Skip to main content

Table 4 The proportion of participants at month 12 who felt they liked the study procedures and clinical services, by study arm (n = 134)

From: Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa

Item

Immediate vaccination

(n = 68) n liked or very liked (%)

Deferred vaccination

(n = 66) n liked or very liked (%)

P

Study procedures

 Informed consent

56 (82.4)

61 (92.4)

0.080

 Randomisation

61 (89.7)

43 (65.2)

0.001

 Completing questionnaires

62 (92.5)

61 (92.4)

0.980

 Physical examination

60 (88.2)

56 (84.9)

0.565

 Genital examination

59 (86.8)

55 (83.3)

0.436

 Collection of blood samples

58 (85.3)

58 (87.9)

0.661

 Repeated HIV testing

68 (100.0)

63 (95.5)

0.075

 Collection of genital samples

59 (86.8)

58 (87.9)

0.846

 Reimbursement

64 (94.1)

65 (98.5)

0.182

 Other study activitiesa

53 (91.4)

52 (91.2)

0.977

Clinical services

 Visit schedules

64 (86.4)

57 (94.1)

0.129

 Travel time to clinic

54 (79.4)

55 (83.3)

0.560

 Clean clinic environment

68 (100.0)

65 (98.5)

0.308

 Waiting time at clinic

67 (98.5)

62 (93.9)

0.161

 Clinic staff attitude

68 (100.0)

65 (98.5)

0.308

 Examination by female nurse

48 (70.6)

51 (77.3)

0.379

 Examination by male nurse

68 (100.0)

63 (95.5)

0.075

 Free treatment and condoms

67 (98.5)

64 (97.0)

0.542

 Free counselling, health information

68 (100.0)

64 (98.5)

0.305

 Hepatitis B vaccinationb

61 (91.0)

-

-

  1. aOther activities included in-depth interviews, focus group discussions and home visits’; bonly for those who received the surrogate vaccine; †chi-square test used to calculate P value